Paganelli G, Bartolomei M, Ferrari M, Cremonesi M, Broggi G, Maira G, Sturiale C, Grana C, Prisco G, Gatti M, Caliceti P, Chinol M
Division of Nuclear Medicine, European Institute of Oncology, Milan, Italy.
Cancer Biother Radiopharm. 2001 Jun;16(3):227-35. doi: 10.1089/10849780152389410.
The aim of this study was to determine the maximum-tolerated dose, of a pre-targeting three-step (3-S) method employing 90Y-biotin in the locoregional radioimmunotherapy (RIT) of recurrent high grade glioma, and to investigate the antitumor efficacy of this new treatment. Twenty-four patients with recurrent glioma underwent second surgical debulking and implantation of a catheter into the surgical resection cavity (SRC), in order to introduce the radioimmunotherapeutic agents [biotinylated monoclonal antibody (MoAb), avidin and 90Y-biotin]. Eight patients with anaplastic astrocytoma (AA) and 16 patients with glioblastoma (GBM) were injected with biotinylated anti-tenascin MoAb (2 mg), then with avidin (10 mg; 24 h later) and finally 90Y-biotin (18 h later). Each patient received two of these treatments 8-10 weeks apart. The injected activity ranged from 0.555 to 1.110 GBq (15-30 mCi). Dosage was escalated by 0.185 GBq (5 mCi) in four consecutive groups. The treatment was well tolerated without acute side effects up to 0.740 GBq (20 mCi). The maximum tolerated activity was 1.110 GBq (30 mCi) limited by neurological toxicity. None of the patients developed hematologic toxicity. In three patients infection occurred around the catheter. The average absorbed dose to the normal brain was minimal compared with that received at the SRC interface. At first control (after 2 months), partial (PR) and minor (MR) responses were observed in three GBM (1 PR; 2 MR) and three AA patients (1 PR; 2 MR) with an overall objective response rate of 25%. Stable disease (SD) was achieved in seven GBM and five AA patients (50%). There was disease progression in six GBM patients (25%), but in none of the AA patients. At the dosage of 0.7-0.9 GBq per cycle, locoregional 3-S-RIT was safe and produced an objective response in 25% of patients. Based on these encouraging results, phase II studies employing 3-S-RIT soon after first debulking are justified.
本研究的目的是确定在复发性高级别胶质瘤的局部区域放射免疫治疗(RIT)中,采用90Y-生物素的预靶向三步(3-S)方法的最大耐受剂量,并研究这种新治疗方法的抗肿瘤疗效。24例复发性胶质瘤患者接受了第二次手术减瘤,并在手术切除腔(SRC)内植入导管,以便引入放射免疫治疗药物[生物素化单克隆抗体(MoAb)、抗生物素蛋白和90Y-生物素]。8例间变性星形细胞瘤(AA)患者和16例胶质母细胞瘤(GBM)患者先注射生物素化抗腱生蛋白MoAb(2mg),然后注射抗生物素蛋白(10mg;24小时后),最后注射90Y-生物素(18小时后)。每位患者在8至10周的间隔内接受两次这样的治疗。注射活度范围为0.555至1.110GBq(15至30mCi)。在连续的四组中,剂量以0.185GBq(5mCi)递增。在高达0.740GBq(20mCi)的剂量下,治疗耐受性良好,无急性副作用。最大耐受活度为1.110GBq(30mCi),受神经毒性限制。没有患者出现血液学毒性。3例患者在导管周围发生感染。与SRC界面处接受的剂量相比,正常脑的平均吸收剂量最小。在首次对照(2个月后)时,3例GBM患者(1例部分缓解;2例轻微缓解)和3例AA患者(1例部分缓解;2例轻微缓解)出现部分缓解(PR)和轻微缓解(MR),总体客观缓解率为25%。7例GBM患者和5例AA患者(50%)病情稳定(SD)。6例GBM患者(25%)病情进展,但AA患者均无病情进展。在每个周期0.7至0.9GBq的剂量下,局部区域3-S-RIT是安全的,25%的患者产生了客观缓解。基于这些令人鼓舞的结果,可以开展在首次减瘤后不久采用3-S-RIT的II期研究。